Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hims and Hers Health Inc (HIMS) vs Phillips 66 (PSX) Price & Performance

Hims and Hers Health IncTrade
Phillips 66Trade

Price performance (Past 24H)

Key statistics

Hims and Hers Health Inc vs Phillips 66 — how do they compare? Hims and Hers Health Inc trades at $29.83 (market cap $7.12B), while Phillips 66 trades at $224.98 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 12.6× Hims and Hers Health Inc's market cap, and Phillips 66 pays a 2.26% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.

HIMSPSX
Market Cap
$7.12B$89.52B
Sector
HealthEnergy
52-Week High
$62.76$224.36
52-Week Low
$14.52$120.04
Enterprise Value
$7.82B$105.99B
Dividend Yield
2.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hims and Hers Health Inc

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.

Phillips 66

Phillips 66 (PSX) trades at $225.04, up 4.41% today, reflecting strong momentum after Q2 2026 earnings beat. The stock shows bullish technical signals with support near $220 and resistance at $227. Fundamentally, the company reported robust Q2 EPS of $9.41, exceeding estimates, driven by high refining margins and operational efficiency. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream assets.

Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a price target of $221.92. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical factors affecting energy markets. The stock's valuation metrics, like P/E of 12.81, suggest room for upside if earnings trends continue.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS

About Phillips 66

Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.

Read more on PSX